Nino Keshelava
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.
Journal: Cancer research communications
Published: March 10, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.
Journal: Frontiers in immunology
Published: October 31, 2025
Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.
Journal: Molecular cancer therapeutics
Published: May 21, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Journal: Cancer research communications
Published: December 17, 2024
Mapping MAGE-A4 expression in solid cancers for targeted therapies.
Journal: Frontiers in oncology
Published: August 21, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 26, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 05, 2023
Last Updated: 09/26/2026